Preparation of integrin α(v)β(3)-targeting Ab 38C2 constructs

Nature Protocols

Volumn 2, Issue 2, 2007, Pages 449-456

  Sinha, Subhash C ^a   Das, Sanjib ^a   Li, Lian Sheng ^a   Lerner, Richard A ^a   Barbas III, Carlos F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ALPHAVBETA5 INTEGRIN; AMINO ACID; DIKETONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 38C2; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTIBODY ALDOLASE; CATALYTIC ANTIBODY; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANTIGEN BINDING; ARTICLE; BINDING SITE; CONJUGATION; ENVIRONMENTAL TEMPERATURE; GENE OVEREXPRESSION; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; DRUG DELIVERY SYSTEM; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY;

ANTIBODIES, CATALYTIC; DRUG DELIVERY SYSTEMS; FRUCTOSE-BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC TECHNIQUES; IMMUNOTHERAPY; INTEGRIN ALPHAVBETA3; MASS SPECTROMETRY;

EID: 34347272702     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2007.3     Document Type: Article

References (13)

1. Hale, G. Therapeutic antibodies: Delivering the promise? Adv. Drug Delivery Rev. 58, 633-639 (2006).
2. Kohzoh, I. & Akinori, T. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714-727 (2006).
3. Rader, C., Sinha, S.C., Popkov, M., Lerner, R.A. & Barbas, C.F., III A chemically programmed monoclonal antibody for cancer therapy. Adapter immunotherapy based on a covalent antibody catalyst. Proc. Natl. Acad. Sci. USA 100, 5396-5400 (2003).
4. Guo, F. et al. Breaking the one antibody one target axiom. Proc. Natl. Acad. Sci. USA 103, 11009-11014 (2006).
5. Popkov, M., Rader, C., Gonzalez, B., Sinha, S.C. & Barbas, C.F., III Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int. J. Cancer 119, 1194-1207 (2006).
6. Doppalaudi, V.R. et. al. Chemically programmed antibodies: Endothelin receptor targeting Cov X-Bodies. Biorg. Med. Chem. Lett. 17, 501-506 (2006).
7. Li, L.-S. et. al. Chemical-adaptor immunotherapy: Design, synthesis and evaluation of novel integrin-targeting devices. J. Med. Chem. 47, 5630-5640 (2004).
8. Wagner, J., Lerner, R.A. & Barbas, C.F., III Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 270, 1797-1800 (1995).
9. Rader, C. et al. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J. Mol. Biol. 332, 889-899 (2003).
10. Kok, R.J. et al. Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics. Bioconjugate Chem. 13, 128-135 (2002).
11. Lu, Y. et al. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in haptenimmunized mice. Mol. Cancer Ther. 5, 3258-3267 (2006).
12. Duggan, M.E. et al. Nonpeptide αvβ3 antagonists. 1. Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αvβ3 antagonist. J. Med. Chem. 43, 3736-3745 (2000).
13. List, B., Barbas, C.F., III & Lerner, R.A. Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis. Proc. Natl. Acad. Sci. USA 95, 15351-15355 (1998).